Synthetic Conjugated Estrogens, B

DB09318

small molecule approved

Deskripsi

Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17?-dihydroequilin sulfate, sodium 17?-estradiol sulfate, sodium 17?­ dihydroequilin sulfate, sodium 17?-dihydroequilenin sulfate, sodium 17?-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17?-estradiol sulfate, and sodium ?8,9-dehydroestrone sulfate. This blend of ten estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered to be equivalent. Available as the product Cenestin (FDA), this combination of plant-derived estrogenic compounds is indicated for the treatment of moderate to severe vasomotor symptoms, vulvovaginal atrophy, vaginal dryness, and paint with intercourse associated with menopause.

All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).

Pharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of baseline-corrected estrone and equilin was found to be 23.46 hr and 15.09 hr, respectively.
Volume Distribusi The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Klirens (Clearance) -

Absorpsi

Synthetic conjugated estrogens, B are soluble in water and are well absorbed from the gastrointestinal tract after release from the drug formulation. The tablets release synthetic conjugated estrogens, B slowly over a period of several hours.

Metabolisme

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).

Rute Eliminasi

Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.

Interaksi Makanan

3 Data
  • 1. Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of synthetic conjugated estrogens, B.
  • 2. Avoid St. John's Wort. This herb induces CYP3A4 metabolism and may reduce serum levels of synthetic conjugated estrogens, B.
  • 3. Take with or without food.

Interaksi Obat

1315 Data
Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Synthetic Conjugated Estrogens, B.
Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
Lenalidomide Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.
Ospemifene The risk or severity of adverse effects can be increased when Synthetic Conjugated Estrogens, B is combined with Ospemifene.
Ropinirole Synthetic Conjugated Estrogens, B may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.
Thalidomide Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Thalidomide.
Cetuximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cetuximab.
Human immunoglobulin G Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G.
Omalizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Omalizumab.
Gemtuzumab ozogamicin Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Trastuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Trastuzumab.
Rituximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rituximab.
Basiliximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Basiliximab.
Muromonab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Muromonab.
Digoxin Immune Fab (Ovine) Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan.
Alemtuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Alemtuzumab.
Capromab pendetide Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide.
Efalizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efalizumab.
Antithymocyte immunoglobulin (rabbit) Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Natalizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Natalizumab.
Palivizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab.
Daclizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daclizumab.
Bevacizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab.
Technetium Tc-99m arcitumomab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Eculizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eculizumab.
Panitumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Panitumumab.
Ranibizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ranibizumab.
Galiximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Galiximab.
Pexelizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pexelizumab.
Epratuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Epratuzumab.
Bectumomab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bectumomab.
Oregovomab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Oregovomab.
IGN311 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IGN311.
Adecatumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Adecatumumab.
Labetuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Labetuzumab.
Matuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Matuzumab.
Fontolizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Fontolizumab.
Bavituximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bavituximab.
CR002 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CR002.
Rozrolimupab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rozrolimupab.
Girentuximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Girentuximab.
Obiltoxaximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Obiltoxaximab.
XTL-001 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of XTL-001.
NAV 1800 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of NAV 1800.
Briakinumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Briakinumab.
Otelixizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Otelixizumab.
AMG 108 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of AMG 108.
Iratumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Iratumumab.
Enokizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Enokizumab.
Ramucirumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ramucirumab.
Farletuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Farletuzumab.
Veltuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Veltuzumab.
Ustekinumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ustekinumab.
PRO-542 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of PRO-542.
TNX-901 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TNX-901.
Inotuzumab ozogamicin Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Inotuzumab ozogamicin.
RI 624 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of RI 624.
Stamulumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of MYO-029.
CT-011 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CT-011.
Leronlimab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Leronlimab.
Glembatumumab vedotin Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Glembatumumab vedotin.
Olaratumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Olaratumab.
IPH 2101 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IPH 2101.
TB-402 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TB-402.
Caplacizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Caplacizumab.
IMC-1C11 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IMC-1C11.
Eldelumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eldelumab.
Lumiliximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lumiliximab.
Nimotuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Nimotuzumab.
Clenoliximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Clenoliximab.
BIIB015 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of BIIB015.
Sonepcizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sonepcizumab.
Motavizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Motavizumab.
Elotuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Elotuzumab.
Carotuximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Carotuximab.
XmAb 2513 Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of XmAb 2513.
Lucatumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lucatumumab.
Pertuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pertuzumab.
Siplizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Siplizumab.
Apolizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Apolizumab.
Sibrotuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sibrotuzumab.
Bivatuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bivatuzumab.
Lerdelimumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lerdelimumab.
Lexatumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lexatumumab.
Reslizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Reslizumab.
Teplizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Teplizumab.
Catumaxomab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Catumaxomab.
Mepolizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Mepolizumab.
Denosumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Denosumab.
Volociximab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Volociximab.
Ofatumumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ofatumumab.
Belimumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Belimumab.
Raxibacumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Raxibacumab.
Obinutuzumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Obinutuzumab.
Vedolizumab Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Vedolizumab.

Target Protein

Estrogen receptor ESR1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 21043366
    Bhamra R, Kaercher U, Oleary CM: Pharmacokinetics of a modified-release estrogen tablet. J Reprod Med. 2010 Sep-Oct;55(9-10):404-10.
Textbook
  • 14. (2015). In Pharmacology for Women’s Health. Jones & Bartlett Publishers.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Enjuvia
    Tablet • 0.9 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet • 0.625 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet • 0.3 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet, film coated • 0.3 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet, film coated • 0.45 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet, film coated • 0.625 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet, film coated • 0.9 mg/1 • Oral • US • Approved
  • Enjuvia
    Tablet, film coated • 1.25 mg/1 • Oral • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul